Company / Cash & Equivalents
GYRE THERAPEUTICS, INC. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$37.1M
FY2025
5-year range
$11.8M / $44.3M
FY2021-FY2025
Trend
+213.8%
vs FY2024
Sector context
#192 of 207
Health Care
What the data says
Cash & Equivalents changed +214% YoY in FY2025, a notable deviation from the 9-year average annual change of +43%.
Based on SEC 10-K filings.
$37M in FY2025 with a 5-year CAGR of +4.1%.
Improved from $34M to $37M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +13.8%
- 5-Year CAGR
- +4.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 207This company $37.1M Sector average $669.5M
▼
-94.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.1%, indicating consistent growth.
- In FY2025, cash & equivalents increased 213.8% year-over-year.
- Ranks #192 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $37.1M | +213.8% |
| FY2024 | $11.8M | -64.7% |
| FY2023 | $33.5M | +33.1% |
| FY2022 | $25.2M | -43.2% |
| FY2021 | $44.3M | +46.1% |
| FY2020 | $30.4M | +97.5% |
| FY2019 | $15.4M | -50.8% |
| FY2018 | $31.2M | +115.7% |
| FY2017 | $14.5M | +41.0% |
| FY2016 | $10.3M | -64.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026